Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efineptakin alfa,Atezolizumab

            Therapeutic Area: Oncology Product Name: NT-I7

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: NeoImmuneTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 21, 2020

            Details:

            This new master agreement will focus initially on a Phase 2 trial in previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer patients, with the goal to evaluate anti-tumor efficacy and safety of the NT-I7 and atezolizumab combination.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tenalisib

            Therapeutic Area: Oncology Product Name: RP6530

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Curon Biopharmaceutical

            Deal Size: $149.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 12, 2020

            Details:

            Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Derazantinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 12, 2020

            Details:

            FGFR inhibitors, including derazantinib, have showed clinical antitumor activity in patients with FGFR2 gene fusion-positive iCCA. To date there is limited clinical evidence for the benefit of FGFR inhibitors in iCCA patients with FGFR2 gene mutations and amplifications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Derazantinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            The FIDES-01 study is a multi-center, open-label phase 2 registrational study of once-daily oral derazantinib for the treatment of patients with inoperable or advanced iCCA and FGFR2 gene fusions or FGFR2 gene mutations or amplifications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Camidanlumab Tesirine

            Therapeutic Area: Oncology Product Name: ADCT-301

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 06, 2020

            Details:

            U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loncastuximab Tesirine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 12, 2020

            Details:

            Interim results of the Phase 1/2 trial of Lonca in combination with ibrutinib show an encouraging overall response rate of 75.0% and complete response rate of 58.3% at the recommended Phase 2 Lonca dose.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loncastuximab Tesirine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 05, 2020

            Details:

            Updated interim data from the pivotal Phase 2 trial of Lonca in patients with relapsed or refactory diffuse large B-cell lymphoma as well as interim results of a Phase 1/2 trial highlighting the potential to advance Lonca into earlier lines of therapy in combination therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loncastuximab Tesirine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            Details:

            Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pracinostat,Azacitidine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            New data from the Phase 2 study evaluating pracinostat in combination with azacitidine in patients with very-high risk myelodysplastic syndromes, will be featured in the ASCO 2020 conference.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loncastuximab Tesirine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 28, 2020

            Details:

            ADC Therapeutics company is developing antibody drug conjugates, cancer drugs that link a tumor-targeting antibody to a cancer-killing chemical compound.

            PharmaCompass